Moore indicated Codexis is scaling up to 100-gram production and aims for 0.5 kilogram by year-end, while also referencing a client’s use of Codexis ligase to manufacture a 3-kilogram batch of ...
A biochemical breakthrough using simple carbon atoms, by Ken Yamada, Ph.D., and Anastasia Khvorova, Ph.D., has dramatically improved the stability and efficacy of a potential oligonucleotide ...
Codexis (NASDAQ:CDXS) used its fourth-quarter and full-year 2025 earnings call to highlight progress behind its strategic ...
Thank you, Georgia, and thanks everyone for joining. At Codexis, Inc., our mission is to generate manufacturing solutions using biocatalytic enzymes. The number of siRNA medicines in development are ...
The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...
Codexis has agreed to manufacture 50 grams of siRNA using its proprietary ECO Synthesis manufacturing platform to support ...
siMecA-AGO2 complex inhibits the translation of the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance phenotype in MRSA. By reducing ...
AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...
Alnylam Pharmaceuticals and PeptiDream are partnering to develop a peptide-based delivery system for Alnylam’s small interfering RNA (siRNA) therapies that silence gene expression. Alnylam has three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results